Vaccine effectiveness against covid-19 related hospital admission by follow-up duration starting 14 days after the second dose and vaccine group
| Follow-up from 14 days after second dose | No of individuals in hospital/Total No in group (%) | Median (IQR) follow-up (days) | Model 1 (HR, 95% CI)* | Model 2 (adjusted HR, 95% CI)† | Vaccine effectiveness (%, 95% CI) |
| ≤1 months | |||||
| BNT162b2—No | 1700/1 299 510 (0.13) | 16 (8-27) | 1 | 1 | — |
| BNT162b2—Yes | 236/1 299 510 (0.02) | 16 (8-27) | 0.13 (0.11 to 0.15) | 0.10 (0.09 to 0.12) | 90 (88 to 91) |
| mRNA-1273—No | 155/148 183 (0.1) | 15 (7-26) | 1 | 1 | — |
| mRNA-1273—Yes | 16/148 183 (0.01) | 16 (7-27) | 0.10 (0.06 to 0.16) | 0.08 (0.05 to 0.15) | 92 (85 to 95) |
| ChAdOx1-S—No | 146/401 700 (0.04) | 22 (12-30) | 1 | 1 | — |
| ChAdOx1-S—Yes | 11/401 700 (0) | 22 (12-30) | 0.07 (0.04 to 0.14) | 0.06 (0.03 to 0.12) | 94 (88 to 97) |
| >1–2 months | |||||
| BNT162b2—No | 1405/812 094 (0.17) | 50 (40-59) | 1 | 1 | — |
| BNT162b2—Yes | 185/812 094 (0.02) | 51 (40-59) | 0.13 (0.11 to 0.15) | 0.11 (0.09 to 0.12) | 89 (88 to 91) |
| mRNA-1273—No | 136/86 852 (0.16) | 50 (40-59) | 1 | 1 | — |
| mRNA-1273—Yes | 12/86 852 (0.01) | 51 (40-59) | 0.08 (0.05 to 0.15) | 0.07 (0.04 to 0.12) | 93 (88 to 96) |
| ChAdOx1-S—No | 277/417 902 (0.07) | 45 (38-53) | 1 | 1 | — |
| ChAdOx1-S—Yes | 35/417 902 (0.01) | 45 (38-53) | 0.13 (0.09 to 0.18) | 0.11 (0.08 to 0.16) | 89 (84 to 92) |
| >2–3 months | |||||
| BNT162b2—No | 1474/789 263 (0.19) | 77 (67-86) | 1 | 1 | — |
| BNT162b2—Yes | 108/789 263 (0.01) | 77 (67-86) | 0.07 (0.06 to 0.09) | 0.06 (0.05 to 0.07) | 94 (93 to 95) |
| mRNA-1273—No | 143/89 122 (0.16) | 76 (66-86) | 1 | 1 | — |
| mRNA-1273—Yes | 7/89 122 (0.01) | 76 (66-86) | 0.05 (0.02 to 0.10) | 0.04 (0.02 to 0.09) | 96 (91 to 98) |
| ChAdOx1-S—No | 174/171 401 (0.1) | 70 (65-77) | 1 | 1 | — |
| ChAdOx1-S—Yes | 13/171 401 (0.01) | 70 (65-77) | 0.07 (0.04 to 0.13) | 0.06 (0.03 to 0.11) | 94 (89 to 97) |
| >3–4 months | |||||
| BNT162b2—No | 1709/558 114 (0.31) | 105 (96-113) | 1 | 1 | — |
| BNT162b2—Yes | 142/558 114 (0.03) | 105 (96-113) | 0.08 (0.07 to 0.10) | 0.06 (0.05 to 0.08) | 94 (92 to 95) |
| mRNA-1273—No | 220/80 794 (0.27) | 103 (95-111) | 1 | 1 | — |
| mRNA-1273—Yes | 8/80 794 (0.01) | 103 (95-111) | 0.04 (0.02 to 0.07) | 0.03 (0.01 to 0.06) | 97 (94 to 99) |
| ChAdOx1-S—No | 20/10 701 (0.19) | 93 (91-98) | 1 | 1 | — |
| ChAdOx1-S—Yes | 3/10 701 (0.03) | 93 (91-98) | 0.15 (0.04 to 0.50) | 0.10 (0.03 to 0.37) | 90 (63 to 97) |
| >4–5 months | |||||
| BNT162b2—No | 1080/146 765 (0.74) | 130 (126-142) | 1 | 1 | — |
| BNT162b2—Yes | 70/146 765 (0.05) | 130(126-142) | 0.06 (0.05 to 0.08) | 0.04 (0.03 to 0.05) | 96 (95 to 97) |
| mRNA-1273—No | 107/16 036 (0.67) | 136 (127-147) | 1 | 1 | — |
| mRNA-1273—Yes | 3/16 036 (0.02) | 136 (127-147) | 0.03 (0.01 to 0.09) | 0.02 (0.01 to 0.06) | 98 (94 to 99) |
| >5–6 months | |||||
| BNT162b2—No | 871/95 266 (0.91) | 163 (157-169) | 1 | 1 | — |
| BNT162b2—Yes | 69/95 266 (0.07) | 163 (157-169) | 0.08 (0.06 to 0.10) | 0.06 (0.05 to 0.08) | 94 (92 to 95) |
| mRNA-1273—No | 70/5630 (1.24) | 157 (154-164) | 1 | 1 | — |
| mRNA-1273—Yes | 2/5630 (0.04) | 157 (154-164) | 0.03 (0.01 to 0.12) | 0.02 (0.00 to 0.07) | 98 (93 to 100) |
| >6 months | |||||
| BNT162b2—No | 11/1086 (1.01) | 183 (182-185) | 1 | 1 | — |
| BNT162b2—Yes | 0/1086 (0.00) | 183 (182-185) | — | — | — |
IQR=interquartile range; HR=hazard ratio; CI=confidence interval; Yes=vaccinated; No=unvaccinated.
*Model 1: adjusted for matching variables (age, sex, region of residence, nursing home status).
†Model 2: Model 1 with further adjustment for social deprivation index, history of positive covid-19 status, history of influenza vaccination, frailty, alcohol related conditions, smoking related conditions, hypertension, diabetes mellitus, dyslipidaemia, obesity related conditions, coronary heart disease, heart failure, cardiac rhythm disorder, valvular heart disease, occlusive peripheral arterial disease, stroke, pulmonary embolism, chronic respiratory conditions, dialysis, having a transplanted kidney, liver failure, active cancer, depression, psychosis, dementia, epilepsy, Parkinson’s disease, inflammatory bowel disease, rheumatoid arthritis, and ankylosing spondylitis.